$PSNL
Personalis, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024122290 Filed on November 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $25.71M
YoY Change 40.89%
Cost Of Revenue $16.96M
YoY Change 14.89%
Gross Profit $8.745M
YoY Change 151.22%
Gross Profit Margin 34.02%
Selling, General & Admin $11.44M
YoY Change -4.4%
% of Gross Profit 130.86%
Research & Development $11.68M
YoY Change -30.2%
% of Gross Profit 133.6%
Depreciation & Amortization $2.800M
YoY Change 0.0%
% of Gross Profit 32.02%
Operating Expenses $23.13M
YoY Change -19.44%
Operating Profit -$14.38M
YoY Change -53.29%
Interest Expense $7.000K
YoY Change -53.33%
% of Operating Profit
Other Income/Expense, Net -$26.08M
YoY Change -81603.13%
Pretax Income -$39.09M
YoY Change 34.45%
Income Tax $3.000K
% Of Pretax Income
Net Earnings -$39.09M
YoY Change 34.34%
Net Earnings / Revenue -152.04%
Basic Earnings Per Share -$0.64
Diluted Earnings Per Share -$0.64
COMMON SHARES
Basic Shares Outstanding 70.65M 53.07M
Diluted Shares Outstanding 61.05M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $143.7M
YoY Change 19.01%
Cash & Equivalents $75.80M
Short-Term Investments $67.85M
Other Short-Term Assets $4.663M
YoY Change -18.19%
Inventory $8.489M
Prepaid Expenses
Receivables $13.47M
Other Receivables $0.00
Total Short-Term Assets $170.3M
YoY Change 14.89%
LONG-TERM ASSETS
Property, Plant & Equipment $50.23M
YoY Change -11.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.563M
YoY Change -26.83%
Total Long-Term Assets $69.61M
YoY Change -11.24%
TOTAL ASSETS
Total Short-Term Assets $170.3M
Total Long-Term Assets $69.61M
Total Assets $239.9M
YoY Change 5.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.45M
YoY Change 38.9%
Accrued Expenses $1.471M
YoY Change -25.52%
Deferred Revenue $3.428M
YoY Change -7.2%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $1.234M
YoY Change 208.5%
Total Short-Term Liabilities $36.41M
YoY Change 12.12%
LONG-TERM LIABILITIES
Long-Term Debt $411.0K
YoY Change
Other Long-Term Liabilities $1.112M
YoY Change -70.63%
Total Long-Term Liabilities $1.112M
YoY Change -70.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.41M
Total Long-Term Liabilities $1.112M
Total Liabilities $73.13M
YoY Change -3.05%
SHAREHOLDERS EQUITY
Retained Earnings -$533.6M
YoY Change 20.68%
Common Stock $700.2M
YoY Change 17.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $166.8M
YoY Change
Total Liabilities & Shareholders Equity $239.9M
YoY Change 5.85%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$39.09M
YoY Change 34.34%
Depreciation, Depletion And Amortization $2.800M
YoY Change 0.0%
Cash From Operating Activities -$6.198M
YoY Change -62.84%
INVESTING ACTIVITIES
Capital Expenditures $247.0K
YoY Change -71.61%
Acquisitions
YoY Change
Other Investing Activities -$27.93M
YoY Change 260.89%
Cash From Investing Activities -$28.18M
YoY Change 227.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 62.43M
YoY Change 21426.21%
NET CHANGE
Cash From Operating Activities -6.198M
Cash From Investing Activities -28.18M
Cash From Financing Activities 62.43M
Net Change In Cash 28.05M
YoY Change -212.24%
FREE CASH FLOW
Cash From Operating Activities -$6.198M
Capital Expenditures $247.0K
Free Cash Flow -$6.445M
YoY Change -63.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001527753
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccountsPayableCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccountsPayableCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38943
dei Entity Registrant Name
EntityRegistrantName
Personalis, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-5411038
dei Entity Address Address Line1
EntityAddressAddressLine1
6600 Dumbarton Circle
dei Entity Address City Or Town
EntityAddressCityOrTown
Fremont
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94555
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
752-1300
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
dei Trading Symbol
TradingSymbol
PSNL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70648084
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75800000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56984000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
67851000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
57195000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13474000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17730000
CY2024Q3 psnl Inventory And Other Deferred Costs
InventoryAndOtherDeferredCosts
8489000
CY2023Q4 psnl Inventory And Other Deferred Costs
InventoryAndOtherDeferredCosts
10474000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4663000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4361000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
170277000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
146744000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50231000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57366000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16816000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17852000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2563000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3137000
CY2024Q3 us-gaap Assets
Assets
239887000
CY2023Q4 us-gaap Assets
Assets
225099000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12450000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14920000
CY2024Q3 psnl Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
20535000
CY2023Q4 psnl Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
23941000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3428000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3288000
CY2023Q4 psnl Warrant Liability Current
WarrantLiabilityCurrent
5085000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
36413000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
47234000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35601000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38321000
CY2023Q4 psnl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
4942000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1112000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5161000
CY2024Q3 us-gaap Liabilities
Liabilities
73126000
CY2023Q4 us-gaap Liabilities
Liabilities
95658000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70638190
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70638190
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50480694
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50480694
CY2024Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
7000
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
5000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
700232000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
598364000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
87000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-222000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-533565000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-468706000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
166761000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
129441000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
239887000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
225099000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25709000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18247000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67814000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53806000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
16964000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
14766000
us-gaap Cost Of Revenue
CostOfRevenue
45539000
us-gaap Cost Of Revenue
CostOfRevenue
40803000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11683000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16738000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37411000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51163000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11444000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11971000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35019000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38202000
CY2023Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
5565000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
5565000
us-gaap Restructuring Charges
RestructuringCharges
4037000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
40091000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
49040000
us-gaap Costs And Expenses
CostsAndExpenses
117969000
us-gaap Costs And Expenses
CostsAndExpenses
139770000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14382000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30793000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50155000
us-gaap Operating Income Loss
OperatingIncomeLoss
-85964000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1384000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1706000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3879000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4424000
CY2024Q3 us-gaap Interest Expense
InterestExpense
7000
CY2023Q3 us-gaap Interest Expense
InterestExpense
15000
us-gaap Interest Expense
InterestExpense
25000
us-gaap Interest Expense
InterestExpense
101000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26081000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18544000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39086000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29070000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64845000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-81634000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
78000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-39089000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-29098000
us-gaap Net Income Loss
NetIncomeLoss
-64859000
us-gaap Net Income Loss
NetIncomeLoss
-81712000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.71
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61051350
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61051350
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48694324
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48694324
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54708205
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54708205
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47701369
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47701369
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-39089000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-29098000
us-gaap Net Income Loss
NetIncomeLoss
-64859000
us-gaap Net Income Loss
NetIncomeLoss
-81712000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
61000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-42000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
34000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-51000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
-199000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-42000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
233000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-51000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
146000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
53000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
76000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
661000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38882000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29087000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64550000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81102000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
112272000
CY2024Q3 psnl Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
46739000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
114000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2677000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
146000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-39089000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
166761000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
176086000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3482000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-42000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
53000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-29098000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
151206000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
129441000
psnl Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
46739000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
114000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
317000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8017000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
233000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
76000
us-gaap Net Income Loss
NetIncomeLoss
-64859000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
166761000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
218139000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
909000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10662000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-51000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
661000
us-gaap Net Income Loss
NetIncomeLoss
-81712000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
151206000
us-gaap Profit Loss
ProfitLoss
-64859000
us-gaap Profit Loss
ProfitLoss
-81712000
us-gaap Share Based Compensation
ShareBasedCompensation
8017000
us-gaap Share Based Compensation
ShareBasedCompensation
10662000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8398000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8389000
psnl Noncash Lease Expense
NoncashLeaseExpense
1036000
psnl Noncash Lease Expense
NoncashLeaseExpense
2681000
psnl Amortization Of Premium Discount On Short Term Investments
AmortizationOfPremiumDiscountOnShortTermInvestments
1826000
psnl Amortization Of Premium Discount On Short Term Investments
AmortizationOfPremiumDiscountOnShortTermInvestments
1400000
psnl Noncash Restructuring And Other Charges
NoncashRestructuringAndOtherCharges
476000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
5565000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-56000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-214000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4255000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2976000
psnl Increase Decrease In Inventories And Other Deferred Costs
IncreaseDecreaseInInventoriesAndOtherDeferredCosts
-1979000
psnl Increase Decrease In Inventories And Other Deferred Costs
IncreaseDecreaseInInventoriesAndOtherDeferredCosts
-201000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-271000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2080000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4135000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-749000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3161000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1018000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3638000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6216000
psnl Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2571000
psnl Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
553000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
550000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-10000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37354000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42840000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
76769000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
71831000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
68000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
103955000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
357000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7387000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
240000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8886000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24737000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30079000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2598000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18438000
psnl Proceeds From Sale Of Common Stock Under Tempus Investment Agreement
ProceedsFromSaleOfCommonStockUnderTempusInvestmentAgreement
17745000
psnl Payment Of Costs Related To Tempus Investment Agreement
PaymentOfCostsRelatedToTempusInvestmentAgreement
800000
psnl Repayments Of Payment Agreements With Financing Entity
RepaymentsOfPaymentAgreementsWithFinancingEntity
822000
psnl Repayments Of Payment Agreements With Financing Entity
RepaymentsOfPaymentAgreementsWithFinancingEntity
2292000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
431000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
909000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65071000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1215000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-15000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-48000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18816000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16936000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58774000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90918000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
77590000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73982000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75800000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72192000
CY2024Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1790000
CY2023Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1790000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
77590000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73982000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationTax
200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The estimates include, but are not limited to, revenue recognition, useful lives assigned to long-lived assets, discount rates for lease accounting, the valuation of stock options, the valuation of common stock warrants, provisions for income taxes, and fair value of lease right-of-use assets. Actual results could differ from these estimates, and such differences could be material to the Company’s consolidated financial position and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25709000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18247000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67814000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53806000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17730000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16642000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3288000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1264000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3928000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7216000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1264000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13474000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17730000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3428000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3288000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
150000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3928000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3578000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7216000
psnl Revenue Performance Obligation Unsatisfied Service Period Description
RevenuePerformanceObligationUnsatisfiedServicePeriodDescription
unfulfilled services under contracts with an original expected duration of more than one year
psnl Contract With Customer Unsatisfied Services Revenue
ContractWithCustomerUnsatisfiedServicesRevenue
1900000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1700000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
200000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2024Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1300000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4100000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
500000
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
500000
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6332000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5661000
CY2024Q3 us-gaap Other Deferred Costs Net
OtherDeferredCostsNet
2157000
CY2023Q4 us-gaap Other Deferred Costs Net
OtherDeferredCostsNet
4813000
CY2024Q3 psnl Inventory And Other Deferred Costs
InventoryAndOtherDeferredCosts
8489000
CY2023Q4 psnl Inventory And Other Deferred Costs
InventoryAndOtherDeferredCosts
10474000
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2800000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2800000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8400000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8400000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
44400000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37700000
CY2024Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1800000
CY2023Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1800000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8161000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12816000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7910000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7761000
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
1234000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
1646000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1471000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
858000
CY2024Q3 psnl Market Development Fees Received From Tempus
MarketDevelopmentFeesReceivedFromTempus
1150000
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
573000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
311000
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
7000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
37000
CY2024Q3 psnl Contract With Customer Deposits Current
ContractWithCustomerDepositsCurrent
29000
CY2023Q4 psnl Contract With Customer Deposits Current
ContractWithCustomerDepositsCurrent
512000
CY2024Q3 psnl Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
20535000
CY2023Q4 psnl Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
23941000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2024Q3 us-gaap Financial Instruments Subject To Mandatory Redemption Settlement Terms Impact Of Changes In Fair Value Of Shares On Number Of Shares
FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsImpactOfChangesInFairValueOfSharesOnNumberOfShares
9218800
CY2024Q3 us-gaap Financial Instrument Subject To Mandatory Redemption Par Value Per Share
FinancialInstrumentSubjectToMandatoryRedemptionParValuePerShare
5.07
CY2024Q3 psnl Financial Instrument Subject To Mandatory Redemption Average Exercise Price Per Share
FinancialInstrumentSubjectToMandatoryRedemptionAverageExercisePricePerShare
2
psnl Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2027-11
CY2024Q3 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
31280
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2064000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8057000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7230000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7189000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5215000
CY2024Q3 psnl Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
42798000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
72553000
CY2024Q3 psnl Lessee Operating Lease Liability Discount On Obligation Amount
LesseeOperatingLeaseLiabilityDiscountOnObligationAmount
29042000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
43511000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7910000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35601000
us-gaap Operating Lease Payments
OperatingLeasePayments
6100000
us-gaap Operating Lease Payments
OperatingLeasePayments
4000000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1300000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1503000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1670000
us-gaap Operating Lease Cost
OperatingLeaseCost
4535000
us-gaap Operating Lease Cost
OperatingLeaseCost
5262000
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
51000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
197000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
175000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
513000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
381000
us-gaap Variable Lease Cost
VariableLeaseCost
1539000
us-gaap Variable Lease Cost
VariableLeaseCost
1264000
CY2024Q3 us-gaap Lease Cost
LeaseCost
2017000
CY2023Q3 us-gaap Lease Cost
LeaseCost
2102000
us-gaap Lease Cost
LeaseCost
6271000
us-gaap Lease Cost
LeaseCost
6701000
CY2023Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
100
CY2023Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
60
CY2023Q4 us-gaap Restructuring And Related Activities Completion Date
RestructuringAndRelatedActivitiesCompletionDate
2024-03-31
CY2023Q1 psnl Restructuring Expenses Related To Disposals Of Fixed Assets And Impairment Of Other Assets
RestructuringExpensesRelatedToDisposalsOfFixedAssetsAndImpairmentOfOtherAssets
600000
CY2024Q3 psnl Shares Subject To Options And Restricted Stock Or Rsu Awards
SharesSubjectToOptionsAndRestrictedStockOrRSUAwards
9620071
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4816129
CY2024Q3 psnl Shares Of Common Stock Reserved For Future Issuance Under Espp
SharesOfCommonStockReservedForFutureIssuanceUnderESPP
192341
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14628541
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.55
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.82
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8257
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8359
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7867
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7873
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7261
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8359
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7847
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7931
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0348
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0415
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0399
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0443
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0348
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0465
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0347
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0443
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2677000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3482000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8017000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10662000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2677000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3482000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8017000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10662000
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p id="note_11_commitments_and_contingencies" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">Note 11. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">Contingencies</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">In June 2024, the Company and Foresight Diagnostics Inc. ("Foresight") entered into a Settlement and License Agreement (the "S&amp;L Agreement") to settle litigation related to alleged patent infringement by Foresight. The Company filed complaints against Foresight—one in August 2022 and a second in June 2023—for infringement of certain of the Company's patents relating to detection of MRD. Foresight filed counterclaims and alleged that its solid tumor recurrence test does not infringe the Company's patents and invalidated two of the Company's patents, and sought to invalidate certain of the Company's other patents, through </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">review proceedings with the U.S. Patent Trial and Appeal Board ("PTAB"). Pursuant to the S&amp;L Agreement, Foresight and the Company agreed to dismiss the pending claims of infringement and related defenses and counterclaims, and to end the remaining </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">review proceedings.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">Under the S&amp;L Agreement, the Company granted Foresight a non-exclusive, worldwide license under certain patents of the Company to develop, manufacture, commercialize and otherwise exploit products and services that use whole genome sequencing and a variable content minimal/molecular residual disease panel that utilizes phased variants in consideration for which Foresight agreed to pay the Company a low single-digit tiered royalty on sales of products and services covered by patents licensed by the Company, subject to customary reductions. The license is perpetual and irrevocable, except in certain limited circumstances, which apply on a patent-by-patent basis. Upon the occurrence of certain specified change of control events with respect to Foresight, the highest percentage of the royalty tiers is subject to a low single-digit increase and Foresight will pay a one-time fee in the low single-digit millions. The term of the S&amp;L Agreement runs through expiration of the patents licensed by the Company to Foresight.</span></p>
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-39089000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-29098000
us-gaap Net Income Loss
NetIncomeLoss
-64859000
us-gaap Net Income Loss
NetIncomeLoss
-81712000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61051350
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61051350
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48694324
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48694324
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54708205
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54708205
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47701369
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47701369
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.71
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9812412
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9756266
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9812412
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9756266

Files In Submission

Name View Source Status
0000950170-24-122290-index-headers.html Edgar Link pending
0000950170-24-122290-index.html Edgar Link pending
0000950170-24-122290.txt Edgar Link pending
0000950170-24-122290-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img80990322_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
psnl-20240930.htm Edgar Link pending
psnl-20240930.xsd Edgar Link pending
psnl-ex10_2.htm Edgar Link pending
psnl-ex31_1.htm Edgar Link pending
psnl-ex31_2.htm Edgar Link pending
psnl-ex32_1.htm Edgar Link pending
psnl-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
psnl-20240930_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending